Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation.
Vesicular stomatitis virus, human immunodeficiency virus type 2, and human foamy virus, which were produced by cell lines expressing galactosyl(alpha1-3)galactosyl (alphaGal) sugars, were found to be less stable in human serum than those from alphaGal-negative cells, indicating that galactosyl(alpha1-3)galactosylation sensitizes these viruses as well as mammalian type C oncoviruses (Rother et al., J. Exp. Med. 182:1345-1355, 1995; Takeuchi et al., Nature (London) 379:85-88, 1996) to complement killing via natural anti-alphaGal antibodies. Thus, virus killing mediated by anti-alphaGal antibodies may play a role as a barrier to animal-to-human infection of various enveloped viruses. Virus vectors for human in vivo gene therapy based on the viruses mentioned above should be produced from alphaGal-negative cells.
Takeuchi
Y
Y
Chester Beatty Laboratories, Institute of Cancer Research, London, England. yasuhiro@icr.ac.uk
Liong
S H
SH
Bieniasz
P D
PD
Jäger
U
U
Porter
C D
CD
Friedman
T
T
McClure
M O
MO
Weiss
R A
RA
D016475:3T3 Cells; D000818:Animals; D001769:Blood / Q000276:immunology*; D002460:Cell Line; D004187:Disaccharides / Q000378:metabolism*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D008562:Membrane Glycoproteins; D051379:Mice; D016092:Spumavirus / Q000276:immunology*; D014721:Vesicular stomatitis Indiana virus / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000502:physiology
D004187:Disaccharides; C028391:G protein, vesicular stomatitis virus; D008562:Membrane Glycoproteins; D014759:Viral Envelope Proteins; C055075:galactosyl-(1-3)galactose